Abstract: Proteases regulate important pathophysiological processes in human body such as homeostasis, blood coagulation, fibrinolysis, tumor progression, etc. These biological effects of proteases largely attribute to their applicability as therapeutic agents. Imbalance in blood coagulation and fibrinolysis, two important physiological processes in human body, leads to thrombosis, a leading cause of cardiovascular complications including myocardial infarction, stroke, etc. The enzymes used to dissolve thrombus (blood clot) are known as thrombolytic agents and among them, the enzymes involving hydrolysis of fibrin called fibrinolytic agents. Thrombolytic agents can be classified according to generation, mechanism of action, source and active site of the enzymes. Among the commercially available thrombolytic agents, uPA and tPA are generally safe but are very expensive. On the other hand, the bacterial streptokinase is a relatively cheap thrombolytic agent but causes undesirable side effects such as bleeding complications. For this reason, worldwide research for potent thrombolytic agents to prevent and treat cardiovascular diseases have been continuing. Microbes are considered as a potential source of as well as safe vectors for expressing thrombolytic and fibrinolytic enzymes. Bacilli are one of the largest groups for this purpose. They have been collected from different traditional fermented foods or have been produced by solid state fermentation using appropriate nutrient substrates including different agro-industrial wastes such as rice straw, molasses, soybean curd residues, etc. This review focuses on different bacterial proteases reported to have potential thrombolytic and fibrinolytic activities.
Proteases are necessary in every aspect of cellular and biological systems. They are ubiquitous and are found in plants, animals and microbes. Based on their presence in living system, they are classified into two groups: intracellular proteases and extracellular proteases. Extracellular enzymes were originally considered as enzymes and used in industry, while intracellular proteases are considered to regulate biochemical reactions in living system. In human body, up-regulation of proteolysis is involved in tumor initiation, progression and metastasis, and causes different types of cancer 5 , while dysregulation of proteolysis is involved in various inflammatory and other diseases. 6 Besides industrial uses, proteases are used as health care product, in diagnostic kit development, and of course as therapeutics in the treatment of various diseases. 7 Since 1978, a number of proteases have been approved by Food and Drug Administration (FDA) for therapeutic applications (Table 1 ) 6 and many are now in clinical trial.
Microorganisms have been considered as preferred sources of the proteases. Bacterial proteases are more Thrombus is a blood clot formed inside the blood vessel by a process called thrombosis. Thrombus formation is one of the major causes of cardiovascular diseases (CVDs), for example, myocardial infarction (commonly known as heart attack), stroke, transient ischemic attack (TIA), venous thromboembolism (VTE) including deep vein thrombosis (DVT), pulmonary embolism (PE), etc. CVDs are the major causes of death globally. 9 As a result, thrombolytic and fibrinolytic agents are gaining more interests day by day. Among the thrombolytic agents, fibrinolytic proteases are considered as the potent agents to treat and prevent CVDs.
10
Blood clotting is a normal physiological process to prevent hemorrhage. Fibrin is the major component of blood clot which is formed from fibrinogen via proteolysis by thrombin. On the other hand, fibrin clots are hydrolyzed by plasmin to avoid thrombosis in blood vessels. During an unbalanced pathophysiological process, hydrolysis of clots may not occur which lead to thrombosis (formation of blood clot).
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Process of blood clotting or thrombus formation
Hemostasis is a process of cessation of blood loss by forming a clot. An obstructive clot when formed inside a blood vessel is called thrombus formation. 12 Hemostasis can be divided into two types: primary hemostasis (immediate platelet activation) and secondary hemostasis (additional coagulation cascade to form fibrin strands). 13 When circulating platelets are exposed directly to the collagen of damaged endothelium, they bind to collagen with different surface glycoproteins. It results in activation of platelet integrins which adhere platelets to the site of injury. 14 Activated platelets change shape from spherical to stellate. They release some chemicals including platelet activating factor (PAF), secretonin, thromboxane A 2 , etc to activate additional platelets and to subsequently increase the affinity of platelets to bind fibrinogen. 15 Secondary hemostasis involves sequential activation of different inactive enzyme precursors known as zymogens by proteolytic activity in which each activate enzyme causes activation of another zymogen 15 which lead to coagulation of blood. The coagulation cascade is divided into three pathways: (i) tissue factor pathway (or extrinsic pathway) (ii) contact activation pathway (or intrinsic pathway) and (iii) final common pathway. 16 Active FX and FV form a prothrombinase complex with prothrombin which is a proteolytic enzyme that activates prothrombin zymogen to active thrombin. 17, 18 During tissue factor pathway, thrombin is formed very rapidly and the amount of FVIIa in blood is higher than other coagulation factors. The main function of thrombin is to convert inactive fibrinogen zymogen to active fibrin monomer which then form hemostatic plug with other constituents. Thrombin also has other functions such as platelet activation, activation of FVIII, FV protein C (in presence of thrombomodulin), FXIII (which helps fibrin polymer to form covalent bond to crosslink) zymogens.
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Thrombolysis and fibrinolysis
The term thrombolysis generally refers to the dissolution of the thrombus while the term fibrinolysis generally refers to the breakdown of fibrin in the blood clot. Fibrin is the end product of the coagulation cascade. Fibrin is dissolved by enzyme plasmin which is a serine protease similar to trypsin. Plasmin is the activated form of plasma zymogen, plasminogen. In human, plasminogen is available as two major glycoforms: type I plasminogen contains two glycosylation molecules and type II plasminogen contains a single glycosylated molecule. Figure 1 . Mechanism of fibrinolysis. tPA= Tissue tipe plasminogen activator; uPA= Urokinase type plasminogen activator; PAI= Plasminogen activator inhibitor; XI=Plasma thromboplastin, an antecedent serine protease; XII=Hageman factor, a serine protease; XIII=Fibrin stabilising factor, a transglutaminase; TAFI= thrombin-activatable fibrinolysis inhibitor; TTC= Thrombomodulinthrombin complex; PC= Protein C; APC= Activated protein C, a= Activated form.
Thrombolytic agents: Classification and sources
Thrombolytic agents are the drugs that are used to dissolve blood clots or thrombus formed inside blood vessel, and reopen the vessels (artery or vein). Various CVDs including heart attack, stroke, deep vein thrombosis (clot in a deep leg vein), pulmonary embolism, etccan be treated using thrombolytic agents. Reteplase (rPA or Retavase), alteplase (tPA or Activase), urokinase (Abbokinase), prourokinase, anisoylated purified streptokinase activator complex (APSAC) and streptokinase are available thrombolytic agents ( Fibrinolytic agents sometimes are also classified into two categories: Fibrin specific agents and non-fibrin specific agents 29 (Table 2) .
However, different thrombolytic agents have different working mechanisms. Based on these mechanisms, the thrombolytic agents are classified into two types. i) Plasminogen activators, which activate plasminogen into active plasmin to degrade fibrin. 60 and Codium latum 61 have been used to screen and characterize different fibrinolytic enzymes in recent years. 
Available thrombolytic agents
A. Tissue plasminogen activator. Tissue plasminogen activator (tPA) is a serine protease and catalyzes the conversion of plasminogen to plasmin and helps in dissolving blood clot. Natural tPA are found in endothelial cells of blood vessels lining, while recombinant tPAs are obtained from microbial sources by recombinant DNA technology. They are used intravenously as thrombolytic agents. The usage of tPA in clinical applications is limited due to short half-life (4-6 min) and high cost of the treatment. tPA is produced as a single chain (sctPA) glycoprotein containing 527 amino acid which is cleaved at Arg 275-Ile276 to a disulphide linked, two chain form (tc-tPA). 62 Both forms exhibit equivalent activity when fibrin bound. 63 The action of tPA on plasminogen is a weak one and the affinity between t-PA and plasminogen is low in absence of fibrin, while is significantly higher in presence of fibrin. t-PA is the major intravascular activator of plasminogen 64 and its gene expression is regulated by histamine, bytyrate, retinoids, arterial levels of shear stress and dexamethanosone independently of PAI-1.
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The three fibrin specific, genetically engineered tissue-type plasminogen activators (r-tPAs) are alteplase, reteplase, and tenecteplase (TNKase). 65 Desmoteplase, another r-tPAs are under Phase III clinical trial and the Danish pharmaceutical company, Lundbeck, holds the worldwide rights for this product. Other recombinant tPAs include lanoteplase, saruplase, anistreplase and pamiteplase (Table 3) . (b) Reteplase: Reteplase is a second generation non-glycosylated r-tPA expressed in Escherichia coli, and was approved by FDA in 1996 for the treatment of AMI. It is a truncated form of tPA and contains 357 amino acids of 527 amino acids of original protein. The innovator Boehringer Mannheim marketed this product in the brand name Retavase®. It has reduced affinity for fibrin as well as the rate of clearance, and increased half-life (13-16 minutes) in plasma because it lacks the N-terminal fibronectin finger, the EGF domain and the first kringle domains compared with the native tPA. For this reason, reteplase can be administered as a double bolus rather than as an infusion, reducing the expense of administration and time. 67, 68 Reteplase has similar efficacy compared to the first-generation tPA, but has less fibrin specificity, and can be administered more conveniently than alteplase.
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(c) Tenecteplase: Tenecteplase, also known as TNK-tPA was approved by the FDA in 2000. It was invented by Genentech Inc and marketed under the brand name of TNKase®. It is a genetically engineered tPA expressed in mammalian cell line, Chinese Hamster Ovary (CHO) cells. TNK-tPA was developed by site-directed mutagenesis of tPA at three sites: a substitution of an asparagines (Asn) residue for threonine (Thr) 103, a substitution of a glutamine residue (Gln) for Asn117 and tetra-alanine substitutions for residues 296-299 in the protease domain. Tenecteplase contains all protein domains present in the first-generation tPA molecule. 69 However, mutation in Thr103 improves protein solubility and extends the proteases circulation halflife by creating a new N-linked glycosylation site, while mutation at Asn117 reduces the clearance rate by eliminating a high mannose glycosylation site, and mutation in residues 296-299 causes limitation to interaction with PAI-1. 70 In humans, the half-life of tenecteplase is 18 minutes 71,72 and compared to alteplase and reteplase, tenectplase is more efficacious than alteplase and reteplase and can be administered as a single bolus.
B. Urokinase or urokinase-type plasminogen activator (uPA). Urokinase is a two chain serine protease and used as a thrombolytic agent in the treatment of pulmonary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots. It is also known as urokinasetype plasminogen activator (uPA) and contains 411 amino acid residues. It is secreted as a single chain glycoprotein named prourokinase (sc-uPA) from endothelial cells, macrophages, renal epithelial cell and some tumor cells. This sc-uPA is converted to a two chain derivative (tc-uPA) following cleavage at Lys158-Ile159 peptide bond by plasmin or kallikrein. 73, 74 uPA has 3 domains: (i) an epidermal growth factor like domain, (ii) a single plasminogen like kringle and (iii) a serine protease domain. 75 But none of these are responsible for binding tc-uPA to fibrin. As a result, it has a low affinity for fibrin relative to tPA and its effectiveness is not affected by the presence or absence of fibrin. 76, 77 In contrast to the less binding capacity of tc-uPA to fibrin, sc-uPA shows a large binding capacity to fibrin but it has a very low plasminogen activating capacity than that of tc-uPA (<1%). 19 
D. Staphylokinase (SAK). Staphylokinase (SAK)
, is a clot specific plasminogen activator obtained from Staphylococcus aureus consisting of 136 amino acid. Even though this specific clot buster found good response in therapy, its use is limited because of its antigenicity and short half-life.
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E. Nattokinase. The fibrinolysis mechanism of NK has been explored more extensively than other microbial fibrinolytic enzymes. NK carries out fibrinolytic activity in multiple mechanisms. i) It directly cleaves cross-linked fibrin as its properties largely resemble that of tPA, ii) It activates the production of tPA, which converts inactive plasminogen to active plasmin. 84, 85 Furthermore, NK enhances its fibrinolysis through cleavage and inactivation of the primary inhibitor of fibrinolysis, PAI-1, and regulates total fibrinolytic activity by its relative ratio with tPA. 86 NK is well-absorbed across the intestinal tract after intraduodenal administration to induce fibrinolysis. 87 Various characteristics of different thrombolytic agents are compred in Table 3 .
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Biosimilar thrombolytic agents
According to FDA, "A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Only minor differences in clinically inactive components are allowable in biosimilar products."As biosimilars (also known as subsequent entry biologics, biogenerics, or biocomparables) are not exactly the same as the originator's product, they are not considered as true generics, but rather are only compared to the originator's product biologically and clinically. Biosimilars are intended to be characterized as to demonstrate a high degree of similarity to the reference product rather than demonstrate clinical benefit and are used at the same dose and for the same indication as the reference productlike true generics. 90 Although no biosimilars are approved in Europe, a great boom of biosimilars is developing in Asia to reduce the high cost of biologics and increased financial burden of Asian governments. 91 92, 93 Elaxim is a biosimilar of tenecteplase from Emcure pharmaceuticals Ltd. which was marketed in 2012 in India. Different marketed thrombolytics and some of their biosimilars are listed in table 4.
Bacillus sp. as a Source of thrombolytic and fibrinolytic proteases
The thrombolytic agents obtained from bacterial sources are considered safe, and the administration of these fibrinolytic agents upon oral administration could increase fibrinolytic activity in human plasma. 94 That is why, these enzymes, especially from the genus Bacillus, could be useful to develop potent thrombolytic agents. 95 Bacillus is a genus of Gram-positive rod-shaped endospore forming bacteria which is a member of the division Firmicutes and produce extracellular proteases during postexponential and stationary phases under most culture conditions. 8 Bacilli have a great diversity of strains.
These strains need different nutritional medium that some may grow well in a solution of glucose, ammonium phosphate and a few mineral salts, some need additional growth factors or amino acids, and others require increasingly complex nutrition. 96 Large-scale production of enzymes such as amylases and proteases is possible because of their ability to excrete these enzymes. 97 
Different traditional fermented foods are important sources of genus
Bacillus that have been found to produce the fibrinolytic enzymes. 36 In 1987, B. natto was first screened from a traditional Japanese soybeanfermented food named natto which produces nattokinase NK. 98 After that, some other bacilli from different fermented foods were discovered (Table 5) 
Production of bacterial thrombolytic and fibrinolytic enzymes from agro-industrial wastes
Enzymes can be produced by submerged fermentation (SmF) and solid state fermentation (SSF). SSF has many advantages over SmF. 95 In SSF, fibrinolytic enzymes are produced using many substrates (Table 6 ). Cost and availability of the substrates, and nutrient composition of the selected solid waste are the main criteria for the selection of an ideal substrate for SSF. Cow dung medium may be considered as a promise and in expensive substrate for fibrinolytic enzyme production. Normally, 80% moisture content is maintained for the production of fibrinolytic enzyme. In SSF, moisture content is one of the critical factors. 115 Cow dung substrate has high moisture-holding capacity, which facilitates the production of fibrinolytic enzyme from bacterial species. The optimum moisture content for enzyme production may vary depending on the organism and substrate used in SSF process. 116 Various carbon and nitrogen sources were used for enhanced production of fibrinolytic enzyme. 115 It was revealed that maximum fibrinolytic enzyme production is favored by starch, followed by sucrose. This result was in agreement with the previous study on proteolytic enzymes from Bacillus sp.
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CONCLUSION
In this review, protease enzymes with their classifications, therapeutic uses, uses as thrombolytic and fibrinolytic agents have been discussed. Different microbial sources of proteases including bacterial proteases as well as their relative studies and production from traditional fermented foods have also been highlighted. Microbial thrombolytic and fibrinolytic enzymes have attracted much more medical interest in recent decades. Proteases produced by Bacillus sp. have been identified to possess thrombolytic and fibrinolytic activities. These proteases are mainly serine proteases such as nattokinase, subtilisin, etc. Exploration of these microbes, specially Bacillus sp. may come out with potential sources of enzymes of pharmaceutical and industrial interests. 
